Hollings Annual Report 2023 FINAL - Flipbook - Page 4
DIRECTOR’S
MESSAGE
Tackling the big challenges
Our mission at MUSC Hollings Cancer Center is
straightforward: to eradicate cancer.
As one of only 72 National Cancer Institute-designated cancer centers in
the nation and the largest academic-based cancer research program in South
Carolina, Hollings’ mission is to reduce the cancer burden in South Carolina
and nationally through innovative research, exceptional education and training,
multidisciplinary patient care, statewide cancer prevention programs, and
progressive public policy transformation.
We aim to find cures and improve the quality of life for those living with cancer.
At Hollings, over 140 specialists across more than 20 academic departments
join forces to study and treat cancer from diverse perspectives. Our three
research programs — cancer biology & immunology, cancer prevention &
control, and developmental cancer therapeutics — create new and better
methods for preventing and treating this complex disease.
With an annual research funding portfolio of more than
$50 million and more than 200 clinical trials, Hollings
focuses on getting this research to where it matters most: in
clinics for the benefit of cancer patients.
We are truly thankful that we continue to attract the
brightest minds in research and medicine and grateful for
our donors who understand how their support impacts
the lives of patients and for our elected officials and
community partners who make the work we do possible
across the state.
We look forward to continuing to lead the state in cancer
research and care so that we can positively impact as many
South Carolinians as possible.
Raymond N. DuBois, M.D., Ph.D.
Director, MUSC Hollings Cancer Center
Associate Provost of Cancer Programs, MUSC
2
Hollings 2023 Annual Report
